Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial

医学 美罗华 内科学 不利影响 临床终点 血管炎 胃肠病学 外科 临床试验 淋巴瘤 疾病
作者
Reza Zonozi,Frank B. Cortazar,Anushya Jeyabalan,Gabriel Sauvage,Pravarut Nithagon,Noah Huizenga,Jillian Rosenthal,Alexander Sipilief,Katherine Cosgrove,Karen Laliberte,Eugene P. Rhee,William F. Pendergraft,John L. Niles
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:83 (3): 351-359 被引量:12
标识
DOI:10.1136/ard-2023-224489
摘要

Objective To compare two long-term remission maintenance strategies for antineutrophil cytoplasmic antibody (ANCA) vasculitis. Methods We conducted a prospective, single-centre, open-label, randomised controlled trial of patients with ANCA vasculitis in remission after completing at least 2 years of fixed-schedule rituximab. In the B cell arm, rituximab was reinfused upon B cell repopulation; in the ANCA arm, rituximab was reinfused upon significant rise in ANCA level. Evaluations were conducted every 3 months. The primary endpoint was clinical relapse, defined as a modified BVAS/WG >0 by 36 months. Secondary endpoints included serious adverse events (SAEs) and rituximab exposure. Results 115 patients were enrolled. Median follow-up time was 4.1 years (IQR 2.5–5.0). By Kaplan-Meier analysis, 4.1% (95% CI 1.0 to 15.6) of patients had a clinical relapse in the B cell arm, compared with 20.5% (95% CI 11.9 to 34.1) in the ANCA arm, at 3 years after study entry (log-rank p=0.045). Total SAEs, including infectious SAEs, and deaths did not differ. The number of SAEs due to COVID-19 was higher in the B cell arm (p=0.049). In the B cell arm, patients received a mean of 3.6 (SD 2.4) infusions (3.6 g) per person over the median study follow-up time of 4.1 years, compared with 0.5 (SD 1.4) infusions (0.5 g) per patient in the ANCA arm (p<0.001). Conclusions Rituximab dosed for B cell repopulation results in fewer clinical relapses than when dosed for a rise in ANCA level in maintenance of remission for ANCA vasculitis. Overall safety was equivalent; SAEs due to COVID-19 and rituximab exposure were higher with the B cell strategy. Trial registration number NCT02749292 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
梅特卡夫完成签到,获得积分10
1秒前
熊雅完成签到,获得积分10
2秒前
4秒前
睡到自然醒完成签到 ,获得积分10
5秒前
cis2014完成签到,获得积分10
7秒前
独特的大有完成签到 ,获得积分10
7秒前
量子星尘发布了新的文献求助10
8秒前
10秒前
xingyi完成签到,获得积分10
12秒前
13秒前
舒心的秋荷完成签到 ,获得积分10
16秒前
zz123发布了新的文献求助10
17秒前
liaomr完成签到 ,获得积分10
17秒前
粗犷的灵松完成签到,获得积分10
18秒前
吃小孩的妖怪完成签到 ,获得积分10
18秒前
ncuwzq完成签到,获得积分10
20秒前
yshj完成签到 ,获得积分10
21秒前
23秒前
净禅完成签到 ,获得积分10
25秒前
27秒前
迷人的寒风完成签到,获得积分10
28秒前
28秒前
water应助科研通管家采纳,获得10
29秒前
Lucas应助HHHAN采纳,获得10
31秒前
无情修杰完成签到 ,获得积分10
32秒前
小柒完成签到 ,获得积分10
34秒前
聪慧芷巧发布了新的文献求助10
35秒前
36秒前
40秒前
蓝意完成签到,获得积分0
41秒前
xiaohongmao完成签到,获得积分10
46秒前
49秒前
qweerrtt完成签到,获得积分10
56秒前
56秒前
与共发布了新的文献求助10
57秒前
carly完成签到 ,获得积分10
58秒前
颢懿完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
ljc完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022